Hola,
Are you new here?

TRANSVASCED

financed

Celiac Disease autoantibodies targeted against transglutaminase 2 repercussions...

Celiac Disease autoantibodies targeted against transglutaminase 2 repercussions in vascular biology disease pathogenesis and treatment Celiac disease (CD) is a common heritable autoimmune disorder triggered by gluten-containing cereals which induce a massive immune reaction and destruction of the small bowel mucosa. The disease is hallmarked by the production of... see more

31/07/2014

UTA

45K€

Project Budget: 45K€

Project leader

TAMPEREEN YLIOPISTO No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

PARTICIPATION DEPralty Sin fecha límite de participación.

Financing granted El organismo FP7 notifico la concesión del proyecto The day 2014-07-31 We do not have the information of the call

0% 100% 100%

characteristics of the participant

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Private Information

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

UTA

0.00€ | Leader

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Project leader

TAMPEREEN YLIOPISTO No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Project Budget 45K€

participation deadline Sin fecha límite de participación.

Project description Celiac disease (CD) is a common heritable autoimmune disorder triggered by gluten-containing cereals which induce a massive immune reaction and destruction of the small bowel mucosa. The disease is hallmarked by the production of antibodies against transglutaminase 2 (TG2), an enzyme involved in angiogenesis. Interestingly CD presents an entire disorganization of the intestinal vasculature where the TG2 autoantibodies are deposited. We recently demonstrated that anti-TG2 antibodies can disrupt and affect the vascular functionality in vitro. Therefore we aimed to study whether antibodies against TG2 can affect vasculature in vivo by increasing TG2 enzymatic activity affecting the extracellular matrix composition and signaling intracellularly. In addition, the inhibition of TG2 enzymatic activity and other molecular pathways can ameliorate the anti-angiogenic effect of CD autoantibodies, offering a potential therapeutical target ordered by the primary users of our study, patients. The results find of the present project will be a step forward in the knowledge of the disease and the pathogenic mechanisms especially those related with the vascular development. To achieve this question, different models of angiogenesis and other molecular methods will be used. Multidisciplinarity is the main strength of the present research combining the knowledge of different fields (molecular biology, clinical observations) as well many collaborations with other researchers and companies. Applicant will contribute with his knowledge about angiogenesis and inflammation while host institution provided the experience in celiac disease research as well the facilities need it making the project feasible. The amount apply is 15,000 € year during 36 month (total 45,000€) to cover consumables, travel and other costs. The present reintegration grant will have a very big impact on applicant future career giving him the possibility to incorporate as a docent in his host organization.

Conecta tu I+D

Entra hoy

Forgot your password?

Financing

Companies

CTIs/Universidades

Projects

researchers